For over 50 years, Guthrie has been conducting oncology clinical trials and we are proud to have been affiliated with multiple institutions, including University of Rochester, Cornell University and Vanderbilt. Our current collaborator for National Cancer Institute (NCI) trials is the Mayo Clinic in Rochester, Minnesota. This collaboration allows access to trials through the NCI’s National Clinical Trials Network (NCTN), a research network that provides treatment, screening, and diagnostic trials to over 3,000 clinical sites across the nation. Through this partnership, we’re able to begin clinical trials quickly, reach conclusions faster and offer studies that incorporate precision medicine and novel therapies that otherwise may not be available.  

Leading-edge research delivered locally - As a Guthrie patient you may have the unique opportunity to take part in one or more of nearly 100 clinical research trials that involve new investigational treatments for many cancer types, and the potential to participate in select trials of novel cancer drugs. If you’re at risk for certain types of cancer, screening and prevention trials are also available. Guthrie research scientists are investigating several projects designed to explore cancer trends in our region and how they may affect the next generation of residents.

Clinical Trials

Clinical trials study new ways to prevent, detect and treat cancer. The NCI approves, oversees and provides funding for a large percentage of oncology clinical trials conducted each year in the United States. Guthrie’s participation in this network provides you access to valuable clinical trials without the burden and expense of traveling to a major metropolitan area.

As a result, you receive excellent care locally from the Guthrie Cancer Center team, while still being able to access cutting edge investigational therapies that are offered in large university settings and metropolitan areas. Clinical cancer trials might involve preventive measures and/or treatments, including chemotherapy, biotherapy, supportive care medications, radiation, experimental surgical techniques or devices, lab draws and/or alternative medicines. 

Your physician can present you with options and help you determine whether a clinical trial is right for you. Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, biotech companies, and the NCTN to offer you the chance to get innovative treatments, novel therapies and to assist with the future of cancer care. 

Title: * Flatiron Health Parent Protocol for Prospective Real World Studies (PrwS Parent Protocol - FH-PrwS-07)

** Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (Substudy Number: FH-PrwS-07-002)
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Flatiron Health, Inc.
Details (Identifier #): NCT06605404
Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06568939
Title: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: Amgen Inc.
Details (Identifier #): 06745323
Title: A Phase 3 Randomized, Double-Blind, Active-Controlled
Study of Palazestrant with Ribociclib Versus Letrozole with
Ribociclib for the First-Line Treatment of ER+, HER2
Advanced Breast Cancer (OPERA-02)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT07085767
Title: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Department: Oncology
Diagnosis: Cancer - Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Olema Pharmaceuticals, Inc.
Details (Identifier #): NCT06016738
Title: A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Department: Vascular Surgery
Diagnosis: Vascular Disease
Principal Investigator:

Marica M.D., Silviu

Sponsors: Becton, Dickinson and Company
Details (Identifier #): NCT06111469
Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

Srivatana MD, Ukorn

Sponsors: Vedanta Biosciences, Inc.
Details (Identifier #): NCT06237452
Title: A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Department: Oncology
Diagnosis: Cancer - Oncology
Principal Investigator:

Wang, Le

Sponsors: Shanghai Henlius Biotech, Inc.
Details (Identifier #): NCT06532006
Title: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of
Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus
Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
Department: Oncology
Diagnosis: Cancer - Lung
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06236438